Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT06518837
This study is recruiting at 6 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hormone Receptor-Positive Breast Cancer
- HER2-Negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rutgers, The State University of New Jersey
- Last updated on ClinicalTrials.gov
- January 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 6
- Trinitas Comprehensive Cancer Center · Elizabeth, NJ
- RWJBarnabas Health - Cooperman Barnabas, Livingston · Livingston, NJ
- RWJBarnabas Health - Monmouth Medical Center · Long Branch, NJ
- Rutgers Cancer Institute · New Brunswick, NJ
- RWJBarnabas Health - Newark Beth Israel Medical Center · Newark, NJ
- RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset · Somerville, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.